Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | PTPRC | P08575 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | CTSK | P43235 | 3/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4343020 | 1.00 | CYP2D6 (0.37) | CYP2D6CA2CA1CA7PTPRC | |
| SCHEMBL5189416 | 0.83 | CYP2D6 (0.40) | CYP2D6CA2CA1CA7PTPRC | |
| SCHEMBL2604479 | 0.83 | CTSK (0.38) | CYP2D6CA2CA1CA7PTPRC | |
| SCHEMBL4334770 | 0.83 | CYP2D6 (0.39) | CYP2D6CA2CA1CA7PTPRC | |
| SCHEMBL26924263 | 0.81 | CYP2D6 (0.42) | CYP2D6CA2CA1CA7PTPRC | |
| SCHEMBL30485492 | 0.81 | CYP2D6 (0.39) | CYP2D6CA2CA1CA7PTPRC | |
| SCHEMBL26924266 | 0.81 | CYP2D6 (0.42) | CYP2D6CA2CA1CA7PTPRC | |
| SCHEMBL23551450 | 0.80 | CYP2D6 (0.38) | CYP2D6CA2CA1CA7PTPRC | |
| SCHEMBL4331287 | 0.79 | PTPRC (0.33) | CYP2D6CA2PTPRCCA12CA14 | |
| SCHEMBL783009 | 0.78 | CA2 (0.41) | CYP2D6CA2CA1CA7PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612068-B2 | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives | H. LUNDBECK A/S (DK) | 2009-11-03 | — | — | US | disclosed |
| US-20060235003-A1 | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives | H. LUNDBECK A/S (DK) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235003-A1 | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives | TYR, TPST2, COMT | CYP2D6 75/4885CA2 4773/4885CA1 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.